Saturday, 17 October 2026European Markets

SALMONES CAMANCHAC Stock Was 22.55% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with SALMONES CAMANCHAC (SACAM.OL) rising 22.55% to kr25.00 on Monday while Oslo Børs Benchmark Index_GI jumped 0.64% to kr1,443.61.

SALMONES CAMANCHAC's last close was kr20.40, 51.89% under its 52-week high of kr42.40.

About SALMONES CAMANCHAC

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-0.86.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.32%.

More news about SALMONES CAMANCHAC (SACAM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com